Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

22.33
+0.78503.64%
Volume:1.90M
Turnover:42.46M
Market Cap:2.24B
PE:-4.83
High:22.76
Open:21.88
Low:21.44
Close:21.54
Loading ...

Beam Therapeutics Inc. Receives FDA Orphan Drug Designation for BEAM-101 in Sickle Cell Disease Treatment

Reuters
·
03 Jun

Beam Therapeutics Inc - Beam-101 Safety Profile Consistent With Busulfan Conditioning

THOMSON REUTERS
·
03 Jun

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease

THOMSON REUTERS
·
03 Jun

Beam Therapeutics treatment of sickle cell disease granted orphan designation

TIPRANKS
·
31 May

Sector Update: Health Care Stocks Fall Pre-Bell Friday

MT Newswires Live
·
30 May

Beam Therapeutics Says FDA Grants Orphan Drug Designation to Lung, Liver Treatment

Dow Jones
·
30 May

Beam Therapeutics receives orphan drug designation for BEAM-302

TIPRANKS
·
30 May

Beam Therapeutics Inc - Initiates Dosing in Fourth Cohort, Data Expected in H2 2025

THOMSON REUTERS
·
30 May

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS
·
30 May

Beam Therapeutics Inc - to Dose First Patient in Part B of Trial in H2 2025

THOMSON REUTERS
·
30 May

Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status

TIPRANKS
·
29 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)

TIPRANKS
·
25 May

Beam Therapeutics Inc. to Participate in RBC Capital Markets Global Healthcare Conference

Reuters
·
13 May

Beam Therapeutics announces FDA grants RMAT designation to BEAM-302

TIPRANKS
·
13 May

Beam Therapeutics Inc. Secures FDA RMAT Designation for BEAM-302 Targeting Alpha-1 Antitrypsin Deficiency

Reuters
·
13 May

Beam Therapeutics- Plans to Dose First Patient in Part B, Which Will Include Aatd Patients With Mild to Moderate Liver Disease, in H2 2025

THOMSON REUTERS
·
13 May

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Beam-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (Aatd)

THOMSON REUTERS
·
13 May

Beam Therapeutics Is Maintained at Equal-Weight by Barclays

Dow Jones
·
07 May

Beam Therapeutics Inc : Guggenheim Cuts Target Price to $55 From $78

THOMSON REUTERS
·
07 May

Beam Therapeutics Inc : Bofa Global Research Raises Price Objective to $43 From $42

THOMSON REUTERS
·
07 May